|1.||Gewirtz, David A: 6 articles (01/2014 - 05/2003)|
|2.||Binderup, Lise: 6 articles (05/2004 - 03/2002)|
|3.||Weigel, Nancy L: 5 articles (09/2014 - 07/2004)|
|4.||Colston, K W: 5 articles (08/2003 - 07/2000)|
|5.||Binderup, L: 5 articles (08/2003 - 04/2000)|
|6.||Bai, Wenlong: 4 articles (04/2015 - 01/2005)|
|7.||Ezzat, Shereen: 4 articles (01/2011 - 02/2002)|
|8.||Asa, Sylvia L: 4 articles (01/2011 - 02/2002)|
|9.||Liu, Wei: 4 articles (01/2011 - 02/2002)|
|10.||Hamberg, K J: 4 articles (08/2003 - 05/2000)|
05/01/2004 - "Assuming that the liver/serum concentration ratio is the same in rats and humans, the concentration of seocalcitol in the human liver is expected to be higher than the concentration resulting in more than 50% inhibition of cancer cell proliferation, and thus pharmacologically effective in HCC. "
08/01/2003 - "All dosing schedules of Seocalcitol were effective in inhibiting tumor progression. "
11/01/2008 - "Results of the present study indicate that EB1089 is an effective growth inhibitor of HCC tumors."
04/01/2015 - "In syngeneic models, ID8 tumors exhibited an increased ability to colonize omenta of VDR null over that of WT mice; pre-treatment of WT, not VDR null, mice with EB1089 reduced ID8 colonization, revealing a role for stromal VDR in suppressing EOC invasion. "
11/10/2011 - "The latency of tumors was markedly prolonged for 30-40 days by Seocalcitol. "
|2.||Breast Neoplasms (Breast Cancer)
08/15/2000 - "These results suggest that EB1089 may be beneficial in the prevention of metastatic bone lesions associated with human breast cancer."
11/01/2006 - "Taken together, these studies suggest that the effect of EB 1089 treatment on the radiation response is related in part to enhanced promotion of autophagic cell death and in part to interference with the proliferative recovery that occurs with radiation alone in p53 wild-type breast tumor cells."
02/01/2003 - "The aim of these studies was to determine the effects of 1,25D(3) and EB1089 on the ER negative, invasive human breast cancer cell line SUM-159PT. "
11/01/2006 - "In contrast, in breast tumor cells lacking p53, where radiation promoted extensive apoptosis and the cells failed to recover after radiation treatment, EB 1089 failed to influence the effect of radiation. "
02/28/2003 - "This data conclusively demonstrate that the induction of cell cycle arrest and apoptosis in breast cancer cells by 1,25D(3), EB1089 and CB1093 is dependent on the nuclear VDR. "
|3.||Prostatic Neoplasms (Prostate Cancer)
02/01/2014 - "EB1089 induced significant expression of genes involved in androgen metabolism in prostate cancer cells. "
02/15/2000 - "Because of these antiproliferative properties in vivo, EB1089 is a potential new therapeutic agent for the treatment of prostate cancer."
06/01/2002 - "We tested the efficacy of the 1,25(OH)(2)D(3) analogue, EB 1089, to chemoprevent prostate cancer in these transgenic mice. "
01/01/2011 - "In the current study, we investigated an FACL3 protein expression and its regulation by 1α, 25(OH)(2)D(3) and its synthetic analogs EB1089 and CB1093 in prostate cancer cells. "
08/01/1997 - "These in vitro studies have shown that the vitamin D3 analogue EB-1089 can significantly reduce the growth rate of the prostate cancer cell line PC-3. "
|4.||Hepatocellular Carcinoma (Hepatoma)
05/01/2000 - "Furthermore, EB 1089 has been shown to induce regression of tumours, especially in hepatocellular carcinoma where complete remission has been obtained. "
11/01/2008 - "Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study."
03/21/1997 - "Studies with the human hepatoma Hep G2 gave rise to 2 isomers of 26-hydroxy EB1089. "
05/01/2013 - "Combination of RA and EB1089 exert synergistic growth inhibition and apoptosis induction on hepatocellular cancers cells."
05/01/2013 - "In the combination group (10 μmol/L RA, 10 nmol/L EB1089), the viability of hepatocellular cancer cells decreased significantly compared with drugs used alone (P < 0.05). "
07/01/2004 - "Analysis of site and cell-specific effects of 1,25-D and EB1089 revealed that 1,25-D was more active than EB1089 in the intestine, the site of calcium absorption, and in inducing osteoclastogenesis and bone resorption whereas EB1089 was more effective in inducing osteoblast differentiation. "
12/01/1995 - "In vitro bone resorption was 2.3 and 17.5 times more potently stimulated by EB1089 and KH1060, respectively. "
02/01/1995 - "Bone resorption was stimulated by 1,25-(OH)2D3 and analogs in a dose-dependent manner with KH1060 and EB1089 being more potent and 1,25-(OH)2D3. "
10/01/1995 - "Studies on two new vitamin D analogs, EB 1089 and KH 1060: effects on bone resorption and osteoclast recruitment in vitro."
02/01/1995 - "The purpose of the present study was to investigate the effect of tamoxifen on 1,25-(OH)2D3- and analogs (EB1089 and KH1060)-stimulated bone resorption in an in vitro model. "
|7.||Megestrol Acetate (Borea)
|8.||Medroxyprogesterone Acetate (Depo-Provera)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)